Patent application number | Description | Published |
20100091974 | RULE-BASED INTELLIGENT CALL FORWARDING - A rule-based intelligent call forwarding system is provided that typically includes a central office, a service control point, and an internet call routing system. The central office typically triggers a query responsive to receiving a call request. The service control point, which is coupled to the central office, receives the query, and triggers an internet call routing query. The internet call routing system, which is coupled to the service control point, typically receives the internet call routing query, determines presence of the called party with respect to a registered communication device, parses rules associated with the called party, and terminates the call request responsive to the rules parsing and presence determination. Methods and other systems are also provided. | 04-15-2010 |
20100215039 | Intelligent Interactive Call Handling - An intelligent interactive call handling system is provided that typically includes a central office, a call-handling device, and an internet call routing system. The central office typically triggers a query responsive to receiving a call request. The call-handling device is coupled to the central office, receives the query, and triggers an internet call routing query. The internet call routing system, which is coupled to the call-handling device, typically receives the internet call routing query, determines presence of the called party with respect to at least one registered communication device, sends a prompt to the called party at said at least one registered communication device responsive to the presence determination, receives a reply from said at least one registered communication device, and routes the call responsive to the reply. Methods and other systems are also provided. | 08-26-2010 |
20130089198 | Intelligent Interactive Call Handling - An intelligent interactive call handling system is provided that typically includes a central office, a call-handling device, and an internet call routing system. The central office typically triggers a query responsive to receiving a call request. The call-handling device is coupled to the central office, receives the query, and triggers an internet call routing query. The internet call routing system, which is coupled to the call-handling device, typically receives the internet call routing query, determines presence of the called party with respect to at least one registered communication device, sends a prompt to the called party at said at least one registered communication device responsive to the presence determination, receives a reply from said at least one registered communication device, and routes the call responsive to the reply. Methods and other systems are also provided. | 04-11-2013 |
Patent application number | Description | Published |
20120064079 | Compositions and Methods for Preventing Erythropoietin-Associated Hypertension - The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor. | 03-15-2012 |
20140120100 | COMPOSITIONS AND METHODS FOR PREVENTING ERYTHROPOIETIN-ASSOCIATED HYPERTENSION - The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor. | 05-01-2014 |
Patent application number | Description | Published |
20090123473 | HUMAN BNP IMMUNOSPECIFIC ANTIBODIES - The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies. | 05-14-2009 |
20090148866 | Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase - The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample. | 06-11-2009 |
20100015637 | PIGF-1 ASSAY AND KITS AND COMPONENTS THEREOF - The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits. | 01-21-2010 |
20110263436 | RECOMBINANT ANTIBODIES AGAINST HEPATITIS C VIRUS AND METHODS OF OBTAINING AND USING SAME - Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection. | 10-27-2011 |